OPEN END TURBO OHNE STOP-LOSS - VIVORYON THERAPEUTICS | Market Closed - Börse Stuttgart 07:15:10 21/05/2024 BST | ||
| 0.57 EUR | +1.79% |
|
| Current month | +11.76% | ||
| 1 month | +159.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VIVORYON THERAPEUTICS N.V.
More news
| Date | Price | Change |
|---|---|---|
| 21/05/24 | 0.57 | +1.79% |
| 20/05/24 | 0.56 | +12.00% |
| 17/05/24 | 0.5 | -1.96% |
| 16/05/24 | 0.51 | +2.00% |
| 15/05/24 | 0.5 | 0.00% |
Delayed Quote Börse Stuttgart
Last update May 21, 2024 at 07:15 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VIVORYON THERAPEUTICS N.V. |
| Issuer | Lang & Schwarz |
| WKN | LX3Y91 |
| ISIN | DE000LX3Y912 |
| Date issued | 06/03/2024 |
| Strike | 0.25 € |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 0.63 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.77 € |
|---|---|
| Lowest since issue | 0.18 € |
Company Profile
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Sector
-
Consensus: Vivoryon Therapeutics N.V.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.8
EUR
Average target price
41.57
EUR
Spread / Average Target
+5,095.83%
- Stock Market
- Certificates
- Certificat
